SAN DIEGO-Neurocrine Biosciences Inc., a local biopharmaceutical company focused on neurological and endocrine diseases and disorders, has disposed of its real estate assets in a $108 million sale-leaseback. The deal is set to close before year’s end.

The buyer and seller were not immediately available for comment, but a public filing by Neurocrine reveals that the firm will sign a 10-year lease to stay in the properties, including its 94,000-sf headquarters property located at 10555 Science Center Dr. Company documents reveal Neurocrine “will receive cash of approximately $60 million net of fees, expenses and existing indebtedness.”

The initial agreement provides options for Neurocrine to repurchase all of the properties. In a released statement, company CFO Timothy P. Coughlin said owning the properties had been a “profitable strategy for the company and our shareholders.” He added that the sale would allow the firm to improve its financial position … (providing) us with the financial flexibility to advance our clinical and research programs and build equity in our pipeline.”

It was a busy day for the firm as it released its Q3 results. The company reported a net loss of $27.2 million, or $0.72 loss per share compared to net loss of $39.1 million, or $1.03 loss per share, for the same period last year. For the nine months ended September 30, 2007, the company reported a net loss of $79.3 million, or $2.09 loss per share compared to net loss of $92.5 million, or $2.46 loss per share, for the same period in 2006. Company officials said, “the decrease in revenues for the three- and nine-month periods is primarily due to the cancellation of our collaboration agreement with Pfizer.”

Neurocrine also announced an exclusive licensing agreement for the development and commercialization of indiplon (an insomnia drug) in Japan with Dainippon Sumitomo Pharma Co Ltd. (DSP). The terms include an initial $20 million to Neurocrine with another $10 million payout upon FDA approval of the drug.

Coughlin said the immediate infusion of $80 million from the sale-leaseback and DSP agreement will bring Neurocrine’s “projected year-end cash balances to near beginning of the year levels.”

In after hours trading, shares of Neurocrine Biosciences (NBIX) gained $0.25, or 2.7%, to $9.50. The 52-week range for NBIX is $7.51 to $14.88.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.



Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join now!

  • Free unlimited access to's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including and

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2024 ALM Global, LLC. All Rights Reserved.